Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Addressing the Gaps in Duration of Treatment for Age-Related Macular Degeneration
Scientific Publications
About EyePoint Pharmaceuticals
EyePoint is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™.
Visit us online: eyepointpharma.com
Follow EyePoint Pharmaceuticals
The EyePoint logo is a registered trademark of EyePoint Pharmaceuticals, Inc.
©2025 EyePoint Pharmaceuticals, Inc. All rights reserved
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU™ is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
DURAVYU (EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™ - efficacy and safety have not yet been established with well controlled, phase 3 pivotal trials.